ACM
STLN

ADAR1 Capital Management’s Starling Oncology STLN Stock Holding History

ADAR1 Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$154K – 343
2026
Q1 		$154K Buy
+50,000
New +$153K 0.01% 272

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ADAR1 Capital Management's STLN Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 50,000 shares — an estimated $154K sold.

ADAR1 Capital Management first reported a position in STLN in Q1 2026 and held it in 1 quarter. The position peaked at $154K in Q1 2026. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 50,000 Starling Oncology shares in Q2 2026, an estimated $154K.
  • ADAR1 Capital Management first reported a position in Starling Oncology in Q1 2026 and held it in 1 quarter.
  • ADAR1 Capital Management's Starling Oncology position peaked at $154K in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.